VectivBio Seeks Slice Of Short Bowel Syndrome Market
As Offering Brings In $125m
Executive Summary
The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.
You may also be interested in...
Ironwood Hits Phase III Endpoint In SBS-IF, But Shareholders Show Wariness
Looking to compete with Takeda’s Gattex in short bowel syndrome with intestinal failure, Ironwood succeeds in a Phase III trial, but investors may be concerned with misses on secondary endpoints.
Ironwood Gears Up To Compete In Competitive Gastrointestinal Markets
With the acquisition of Swiss biotech firm VectivBio in late June, Ironwood Pharmaceuticals has firmly positioned itself as a gastrointestinal-focused company.
Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess
Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.